Kura Oncology (KURA) Announces Preliminary Clinical & Pre-Clinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Kura Oncology, Inc. (NASDAQ: KURA) today announced that clinical and preclinical data for tipifarnib in the treatment of relapsed or ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)